Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Lung Cancer: Targets and Therapy · 2019-02 · Volume 10 · 11-20
DOI: 10.2147/lctt.s179349 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2019-02. Verfasst von Stephanie M Barrows und 7 weiteren Autor:innen. Beteiligte Einrichtung: Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.
- Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA.
- Medical Affairs, Pfizer, Inc., New York, NY, USA.
- Medical Affairs, Pfizer Limited, Walton Oaks, UK.
- Medical Affairs, Pfizer, Inc., Oslo, Norway.
- Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA.
Zitieren
APA
Barrows, S. M., Wright, K., Copley-Merriman, C., Kaye, J. A., Chioda, M., Wiltshire, R., Torgersen, K. M., & Masters, E. T. (2019). Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer: Targets and Therapy, Volume 10, 11-20. https://doi.org/10.2147/lctt.s179349
Vancouver
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, et al. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer: Targets and Therapy. 2019;Volume 10:11-20. doi:10.2147/lctt.s179349
BibTeX
@article{Barrows2019,
author = {Barrows, Stephanie M and Wright, Kelly and Copley-Merriman, Catherine and Kaye, James A and Chioda, Marc and Wiltshire, Robin and Torgersen, Knut Martin and Masters, Elizabeth T},
title = {Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer},
journal = {Lung Cancer: Targets and Therapy},
year = {2019},
volume = {Volume 10},
pages = {11--20},
doi = {10.2147/lctt.s179349}
}
EUVIMED